

# **Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2018**

<https://marketpublishers.com/r/MA614116DF3EN.html>

Date: September 2018

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: MA614116DF3EN

## **Abstracts**

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2018

### **SUMMARY**

According to the recently published report 'Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2018'; Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Macrophage migration inhibitory factor (MIF) also known as glycosylation-inhibiting factor (GIF) is a protein that is encoded by the MIF gene. Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine produced by the pituitary gland and multiple cell types, including macrophages, dendritic cells (DC) and T-cells. Upon releases MIF modulates the expression of several inflammatory molecules, such as TNF- $\alpha$ , nitric oxide and cyclooxygenase 2 (COX-2). MIF is an important regulator of innate immunity. Antigens stimulate white blood cells to

release MIF into the blood stream. The circulating MIF binds to CD74 on other immune cells and trigger an acute immune response. MIF plays a role in the regulation of macrophage function in host defense through the suppression of anti-inflammatory effects of glucocorticoid.

The report 'Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2018' outlays comprehensive information on the Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 8 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Dermatology, Infectious Disease, Respiratory and Toxicology which include indications Glomerulonephritis, Inflammatory Bowel Disease, Pulmonary Arterial Hypertension, Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes), Alcohol Addiction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Asthma, Atopic Dermatitis (Atopic Eczema), Chemotherapy Induced Peripheral Neuropathy, Crohn's Disease (Regional Enteritis), Drug Addiction, Globoid Cell Leukodystrophy (Krabbe Disease), Malaria, Multiple Sclerosis, Myocardial Infarction, Obesity, Opium Withdrawal Syndrome, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Psoriasis, Recurrent Glioblastoma Multiforme (GBM), Secondary Progressive Multiple Sclerosis (SPMS), Spinal Cord Disorders, Systemic Lupus Erythematosus, Type 2 Diabetes and Ulcerative Colitis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

*Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachr...*

The report provides a snapshot of the global therapeutic landscape for Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12)

The report reviews Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics and enlists all their major and minor projects

The report assesses Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Overview

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Companies Involved in Therapeutics Development

GlaxoSmithKline Plc

Kyorin Pharmaceutical Co Ltd

Shire Plc

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Drug Profiles

BaxB-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BaxG-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibudilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-88 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

malaria vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MFC-1040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MFC-2040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIF-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibits MIF for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-425 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit MIF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Macrophage Migration Inhibitory Factor for Type 1 Diabetes -  
Drug Profile

Product Description

*Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachr...*

## Mechanism Of Action

## R&D Progress

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Dormant Products

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Discontinued Products

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Product Development Milestones

## Featured News & Press Releases

Aug 31, 2018: MediciNova reports positive results from SPRINT-MS trial

Aug 31, 2018: Multiple sclerosis drug slows brain shrinkage in NIH-funded trial

Aug 22, 2018: MediciNova to receive NIAAA funding for Phase IIb trial of MN-166

Aug 08, 2018: MediciNova to start Phase II/III trial of MN-166 for DCM

Jul 31, 2018: MediciNova announces MN-166 (ibudilast) ALS abstract accepted for presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK

Jul 29, 2018: MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial

Jul 13, 2018: Yale researchers identify target for novel malaria vaccine

Jul 09, 2018: MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS

May 09, 2018: MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma

May 07, 2018: MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal

Apr 26, 2018: MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology 70th Annual Meeting

Apr 24, 2018: MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data

Mar 29, 2018: MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence

Feb 18, 2018: MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology 70th Annual Meeting



Feb 01, 2018: MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression in the SPRINT-MS Phase 2b Trial in Progressive MS: Potential Best-in-Disease Drug

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indications, H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Number of Products under Investigation by Universities/Institutes, H2 2018  
Products under Investigation by Universities/Institutes, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by GlaxoSmithKline Plc, H2 2018  
Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018  
Pipeline by Shire Plc, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd.1), H2 2018  
Discontinued Products, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

GlaxoSmithKline Plc

Kyorin Pharmaceutical Co Ltd

Shire Plc

## I would like to order

Product name: Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/MA614116DF3EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MA614116DF3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970